home / stock / rare / rare quote
Last: | $46.59 |
---|---|
Change Percent: | -1.2% |
Open: | $47.94 |
Close: | $46.59 |
High: | $47.94 |
Low: | $46.53 |
Volume: | 739,242 |
Last Trade Date Time: | 03/18/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$46.59 | $47.94 | $46.59 | $47.94 | $46.53 | 739,242 | 03-18-2024 |
$47.37 | $46.61 | $47.37 | $47.63 | $46.22 | 1,792,072 | 03-15-2024 |
$46.65 | $47.85 | $46.65 | $48.18 | $46.47 | 1,090,127 | 03-14-2024 |
$48.55 | $47.82 | $48.55 | $49.27 | $47.595 | 847,958 | 03-13-2024 |
$47.66 | $48.26 | $47.66 | $48.76 | $47.315 | 549,031 | 03-12-2024 |
$48.51 | $50.66 | $48.51 | $50.95 | $48.4 | 639,244 | 03-11-2024 |
$50.53 | $51.42 | $50.53 | $51.74 | $50.16 | 501,019 | 03-08-2024 |
$50.85 | $51.65 | $50.85 | $52.09 | $50.49 | 554,645 | 03-07-2024 |
$51.26 | $51.42 | $51.26 | $51.7727 | $50.88 | 435,079 | 03-06-2024 |
$51.47 | $52.62 | $51.47 | $53.25 | $50.14 | 790,576 | 03-05-2024 |
$53.31 | $53.76 | $53.31 | $53.77 | $52.0075 | 692,941 | 03-04-2024 |
$53.69 | $52.23 | $53.69 | $54.56 | $52.0275 | 743,830 | 03-01-2024 |
$51.72 | $53.68 | $51.72 | $54.39 | $51.68 | 1,347,322 | 02-29-2024 |
$52.75 | $53.66 | $52.75 | $54.48 | $52.575 | 924,222 | 02-28-2024 |
$53.66 | $50.97 | $53.66 | $53.9 | $50.7 | 910,705 | 02-27-2024 |
$50.25 | $49.43 | $50.25 | $50.7089 | $49.09 | 553,606 | 02-26-2024 |
$49.48 | $48.78 | $49.48 | $50.22 | $48.745 | 454,394 | 02-23-2024 |
$48.88 | $48 | $48.88 | $49.36 | $47.485 | 395,388 | 02-22-2024 |
$48.18 | $47.96 | $48.18 | $48.53 | $47.67 | 456,589 | 02-21-2024 |
$47.87 | $48.47 | $47.87 | $49.73 | $47.29 | 706,673 | 02-20-2024 |
News, Short Squeeze, Breakout and More Instantly...
Ultragenyx Pharmaceutical Inc. Company Name:
RARE Stock Symbol:
NASDAQ Market:
Ultragenyx Pharmaceutical Inc. Website:
2024-03-18 11:30:02 ET Wedbush analyst issues BUY recommendation for RARE on March 18, 2024 09:00AM ET. The previous analyst recommendation was Buy. RARE was trading at $47.78 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...
44th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26th Annual Global Healthcare...
44 th Annual Cowen Healthcare Conference on March 4 Leerink Partners Global Biopharma Conference on March 12 Barclays 26 th Annual Global Healthcare Conference on March 13 NOVATO, Calif., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceut...